S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines

References

• Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6 Suppl 1(1):2–8.
   PubMedGoogle Scholar
• Kobayakawa M, Kojima Y. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther. 2011;4:193.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Guengerich F. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica. 1996;26(4):395–403.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Jacobs BA, Aliev A, et al. Increased risk of severe fluoropyrimidine‐associated toxicity in patients carrying a G> C Substitution in the First 28‐bp tandem repeat of the thymidylate synthase 2R Allele. Int J Cancer. 2016 Jan 1;138(1):245–253.
   Web of Science ®Google Scholar
• Dranitsaris G, Lacouture ME. Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast Cancer Res Treat. 2014;147(3):631–638.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, El Halawani H, Essam-Eldin S. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury; a Meta-analysis with comparison to other fluoropyrimidines. Expert Opin Drug Saf. 2016 Jan;15(1):5–20.
   Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Definition of adverse events [Internet]. [ cited 2015 Aug 2]. Available from: http://www.meddra.org/about-meddra/organisation.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Higgins JP. Measuring inconsistency in meta-analyses. BMJ: Br Med J. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Yamamoto D, Iwase S, Tsubota Y, et al. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. Cancer Chemother Pharmacol. 2015;75(6):1183–1189.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Lee J-L, Kim TW, et al. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol. 2012;51(7):860–866.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820.
   PubMed Web of Science ®Google Scholar
• Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15(8):886–893.
   PubMed Web of Science ®Google Scholar
• Lee SS, Jeung H-C, Chung HC, et al. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Invest New Drugs. 2012;30(1):357–363.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–1553.
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10(11):1063–1069.
   PubMed Web of Science ®Google Scholar
• Huang D, Ba Y, Xiong J, et al. A multicentre randomised trial comparing weekly paclitaxel+ S-1 with weekly paclitaxel+ 5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer. 2013;49(14):2995–3002.
   PubMed Web of Science ®Google Scholar
• Nishikawa K, Morita S, Matsui T, et al. A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer. 2012;15(4):363–369.
   PubMed Web of Science ®Google Scholar
• Kim GM, Jeung H-C, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518–526.
   PubMed Web of Science ®Google Scholar
• Lee J, Kang Y, Kang H, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 2008;99(4):584–590.
   PubMed Web of Science ®Google Scholar
• Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 2012;13(11):1125–1132.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Kuwano H, Ojima H, et al. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015;75(3):569–577.
   PubMed Web of Science ®Google Scholar
• Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11(9):853–860.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14(13):1278–1286.
   PubMed Web of Science ®Google Scholar
• Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 2015 Jul;26(7):1401–1408.
   PubMed Web of Science ®Google Scholar
• Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010;28(36):5240–5246.
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol. 2013 May;24(5):1326–1331.
   Web of Science ®Google Scholar
• Yao L, Xu S, Xu J, et al. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial. Radiation Oncology. 2015;10(1):10.
   PubMed Web of Science ®Google Scholar
• Shukuya T, Takahashi T, Harada H, et al. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. Anticancer Res. 2012;32(2):675–680.
   PubMed Web of Science ®Google Scholar
• Nakai Y, Isayama H, Sasaki T, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer. 2012;106(12):1934–1939.
   PubMed Web of Science ®Google Scholar
• Sudo K, Ishihara T, Hirata N, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2014;73(2):389–396.
   PubMed Web of Science ®Google Scholar
• Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640–1648.
   PubMed Web of Science ®Google Scholar
• Ozaka M, Matsumura Y, Ishii H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol. 2012;69(5):1197–1204.
   PubMed Web of Science ®Google Scholar
• Nishino K, Imamura F, Kumagai T, et al. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). Lung Cancer. 2015;89(2):146–153.
   PubMed Web of Science ®Google Scholar
• Seto T, Sasaki T, Yamanaka T, et al. editors. A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L. ASCO Annual Meeting Proceedings; 2015.
   Google Scholar
• Segawa Y, Kiura K, Hotta K, et al. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. J Thorac Oncol. 2010;5(9):1430–1434.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab; a Meta analysis. Future Oncol. 2015 Nov;11(21):2949–2961.
   Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–3051.
   PubMed Web of Science ®Google Scholar
• Innes H, Lim SL, Hall A, et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008;16(5):485–491.
   PubMed Web of Science ®Google Scholar
• Hämäläinen S, Kuittinen T, Matinlauri I, et al. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. Leuk Lymphoma. 2008;49(3):495–501.
   PubMed Web of Science ®Google Scholar
• NCCN guidelines for myeloid growth factors [Internet]. [ cited 2015 Aug 26]. http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf.
   Google Scholar
• NCCN guidelines for infections in cancer patients [Internet]. [cited 2015 Aug 26]. http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.
   Google Scholar
• Kijima T, Shimizu T, Nonen S, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol. 2011;29(19):e588–e90.
   PubMed Web of Science ®Google Scholar
• Ye J, Chen J, Ge L, et al. Effectiveness and safety of S-1-based therapy compared with 5-fluorouracil-based therapy for advanced colorectal cancer: a meta-analysis. Gastroenterol Res Practice. 2014;2014.
   Web of Science ®Google Scholar
• Yang J, Zhou Y, Min K, et al. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: A meta-analysis. World J Gastroenterology: WJG. 2014;20(33):11886.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Matsumoto S, Teramukai S, et al. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer. 2007;97(1):37–42.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006;80(3):282–297.
   PubMed Web of Science ®Google Scholar